303 related articles for article (PubMed ID: 28933312)
1. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
[TBL] [Abstract][Full Text] [Related]
2. CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.
Zhao Y; Masiello D; McMillian M; Nguyen C; Wu Y; Melendez E; Smbatyan G; Kida A; He Y; Teo JL; Kahn M
Oncogene; 2016 Jul; 35(28):3705-17. PubMed ID: 26657156
[TBL] [Abstract][Full Text] [Related]
3. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
5. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.
Chimge NO; Chen MH; Nguyen C; Zhao Y; Wu X; Gonzalez PG; Ogana H; Hurwitz S; Teo JL; Chen X; Du J; Jin V; Kim YM; Ono M; Argüello RJ; Kahn M
Curr Mol Pharmacol; 2024; 17(1):e060923220758. PubMed ID: 37691195
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
[TBL] [Abstract][Full Text] [Related]
7. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
[TBL] [Abstract][Full Text] [Related]
8. The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells.
Kim YM; Ma H; Oehler VG; Gang EJ; Nguyen C; Masiello D; Liu H; Zhao Y; Radich J; Kahn M
Curr Cancer Drug Targets; 2011 Feb; 11(2):213-25. PubMed ID: 21158719
[TBL] [Abstract][Full Text] [Related]
9. Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose.
Bono S; Dello Sbarba P; Lulli M
Stem Cell Res; 2018 Apr; 28():33-38. PubMed ID: 29414416
[TBL] [Abstract][Full Text] [Related]
10. Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34
Dolinska M; Piccini A; Wong WM; Gelali E; Johansson AS; Klang J; Xiao P; Yektaei-Karin E; Strömberg UO; Mustjoki S; Stenke L; Ekblom M; Qian H
Biochem Biophys Res Commun; 2017 Aug; 490(2):378-384. PubMed ID: 28623130
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
12. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
13. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
Chorzalska A; Ahsan N; Rao RSP; Roder K; Yu X; Morgan J; Tepper A; Hines S; Zhang P; Treaba DO; Zhao TC; Olszewski AJ; Reagan JL; Liang O; Gruppuso PA; Dubielecka PM
Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707
[TBL] [Abstract][Full Text] [Related]
15. Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function.
Lin LC; Yeh CT; Kuo CC; Lee CM; Yen GC; Wang LS; Wu CH; Yang WC; Wu AT
J Agric Food Chem; 2012 Jul; 60(28):7031-9. PubMed ID: 22708678
[TBL] [Abstract][Full Text] [Related]
16. CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome.
Fathy El-Metwaly N; Aref S; Ayed M; Abdel Hamid M; El-Sokkary AMA
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3237-3243. PubMed ID: 34711000
[TBL] [Abstract][Full Text] [Related]
17. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
[TBL] [Abstract][Full Text] [Related]
18. CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
Moreno-Lorenzana D; Avilés-Vazquez S; Sandoval Esquivel MA; Alvarado-Moreno A; Ortiz-Navarrete V; Torres-Martínez H; Ayala-Sánchez M; Mayani H; Chavez-Gonzalez A
Cell Cycle; 2016 May; 15(9):1276-87. PubMed ID: 26985855
[TBL] [Abstract][Full Text] [Related]
19. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
[TBL] [Abstract][Full Text] [Related]
20. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
